X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Lowered to $4.00 at Stifel Nicolaus

X4 Pharmaceuticals (NASDAQ:XFOR) had its target price lowered by Stifel Nicolaus from $5.00 to $4.00 in a report released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. The stock has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.75. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The firm has a market capitalization of $67.99 million, a P/E ratio of -4.48 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The business had revenue of $3.43 million for the quarter. As a group, analysts anticipate that X4 Pharmaceuticals will post -0.65 EPS for the current fiscal year.

Insider Transactions at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the transaction, the chief executive officer now owns 1,057,713 shares in the company, valued at approximately $581,742.15. This represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 580,800 shares of company stock worth $321,447. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in XFOR. Price T Rowe Associates Inc. MD lifted its stake in X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after buying an additional 12,514 shares during the period. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at about $30,000. SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at about $37,000. XTX Topco Ltd acquired a new position in X4 Pharmaceuticals in the second quarter valued at about $65,000. Finally, Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the period. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.